Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

l mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers. In previously conducted randomized trials, Xcytrin combined with whole brain radiation therapy (WBRT) has been shown to prolong time to neurologic progression in patients with brain metastases from NSCLC. Xcytrin's non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy regimens.

The target for Xcytrin is the enzyme thioredoxin reductase, which is frequently overexpressed in lung cancer cells. This enzyme has been shown to confer to cancer cells characteristics of aggressive tumor growth and resistance to chemotherapy. First-line therapy for advanced NSCLC includes combination chemotherapy using drugs such as carboplatin, cisplatin, Gemzar(R), taxanes and others. Currently approved agents for second-line treatment of NSCLC include Alimta, Tarceva(R) and Taxotere.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with WBRT for treatment of brain metastases from NSCLC was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. In addition, more information about advocacy on behalf of Xcytrin can be found at




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the following equities: ... Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... Novartis AG (NYSE: NVS ). Free research on ... . On Friday, December 12, 2014, the NASDAQ Composite ... lost 1.79%, to finish the day at 17,280.83, and the ...
(Date:12/15/2014)... and BOSTON , December 15, 2014 ... structure-guided drug discovery and development company, is pleased to ... the United States relating to its ... in the US significantly strengthens the global patent estate ... markets. The suite of patents recently granted ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... Clot Retention and Decreases Residual Clot Volume , ... Cardiovascular LLC announced today that data presented at the ... Cardiothoracic Surgery show that administration of a heparin bolus ... vein harvest (EVH) was associated with improved acute saphenous ...
... , --First of 2 data sets to be released-- ... from two randomized, active-controlled clinical trials in patients with blepharospasm ... upper limb spasticity trial -- were presented at the Movement ... The studies were sponsored by Merz Pharmaceuticals, which plans to ...
Cached Medicine Technology:Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients 2Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:12/17/2014)... Mozes HealthDay Reporter , TUESDAY, ... infectious diseases, one worrisome phenomenon is when an illness that ... -- known as zoonosis -- is not uncommon and keeps ... an animal-borne disease might make inroads into the human population. ... -- and the culprits in this case were guinea pigs. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... improve overall health, but a growing body of evidence shows ... review finds. In fact, the benefits were similar to ... researcher Paula Chu, a doctoral candidate at Harvard University,s Health ... trials, found that people randomly assigned to take yoga classes ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ... on a new study providing evidence on the impact ... of children. , Sufficient enough evidence already exists showing ... or juice drinks, with the onset of tooth decay. ... drinks listed as 100% fruit juice, meaning it is ...
(Date:12/15/2014)... By Steven Reinberg ... -- A large, new study should reassure the millions of ... the risk for breast cancer. "There is no association ... Tamimi, an associate professor of medicine at Harvard Medical School. ... for concern, and there is no protective effect either." ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
Breaking Medicine News(10 mins):Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... a chlorine gas disaster in a South Carolina town gives ... how to prepare emergency response systems for an accidental or ... now available in the January 2009 issue of the ... one of the largest community exposures to chlorine gas since ...
... of chronic abdominal pain of luminal etiology is a ... The exact localization of lesion to either small or ... In tropical countries, where most of the population is ... which screens small and large bowel lesions simultaneously at ...
... 29 Stereotaxis, Inc.,(Nasdaq: STXS ) today ... existing institutional investors to raise gross proceeds of $20,million ... two separate,concurrent transactions. A portion of the warrants sold ... these warrants would provide an additional,approximately $10 million in ...
... study finds , , MONDAY, Dec. 29 (HealthDay News) -- ... have sex as teens who don,t make such promises -- ... disease or pregnancy, a new study finds. , "Previous studies ... than non-pledgers," said study author Janet E. Rosenbaum, a post ...
... 5k Walks Drive Home Importance of Awareness and Education ... an effort to raise money for The Kidney TRUST(TM) ... of chronic kidney disease (CKD) -- DaVita Inc., the ... that the 3rd annual "Kidney Awareness Time(TM)" Walk-a-thon (The ...
... Free Company Plans New Products and Expanded Services in 2009 ... ... Vista, LLC has reported its seventh consecutive year of revenue growth ... and strong demand for media relations and marketing services provided by ...
Cached Medicine News:Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 2Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 3Health News:A new screening test for chronic abdominal pain 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 3Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 4Health News:Many Teens Don't Keep Virginity Pledges 2Health News:Many Teens Don't Keep Virginity Pledges 3Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 2Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 3Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: